Molecular and genomic predictors of response to single-agent doxorubicin (ADR) versus single-agent docetaxel (DOC) in primary breast cancer (PBC). Background: In women 70 years of age or older with ...
Patients with ductal carcinoma in situ (DCIS) are often treated with radiation after lumpectomy, although it has remained unclear whether this can reduce the risk of dying from this noninvasive form ...
Despite evidence that use of adjuvant radiation therapy (RT) after lumpectomy yields no survival benefit for elderly women (aged 70 years and older) with small, estrogen-receptor-positive (ER+) breast ...
Recommendation to omit radiation therapy after lumpectomy is not frequently implemented Most elderly breast cancer patients who could skip radiation still get it Date: January 27, 2016 Source: ...
Male breast cancer: Looking for prognostic subgroups. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract does not include a full text component.
(HealthDay)—Treatment with lumpectomy and radiotherapy is associated with a reduction in breast cancer mortality versus lumpectomy or mastectomy alone among patients with ductal carcinoma in situ ...
The identification of the tumor bed following lumpectomy is vital for successful radiation treatment, both for a breast radiation boost and more fundamentally in the partial breast setting. However, ...
Despite clinical trial evidence and recommendations that certain older breast cancer patients can forego radiation therapy after lumpectomy, most older patients continue to receive radiation therapy, ...
Add Yahoo as a preferred source to see more of our stories on Google. If youve been recently diagnosed with breast cancer, one of the first decisions you may face is which type of surgery to have. The ...
“You know that phrase, ‘third time’s the charm?’ ” Marilene Nevins asks. Well, not always. In 1997, a suspicious mass was found in Nevins’ right breast. “I nicknamed that one Mickey,” she says. “You ...
The FDA has granted the ProSense Cryoablation System marketing authorization for small, low-risk breast cancers in women at least 70 years of age who receive adjuvant endocrine therapy. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results